ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)

China flag China · Delayed Price · Currency is CNY
13.50
+0.69 (5.39%)
Apr 30, 2026, 3:08 PM CST
55.71%
Market Cap 3.46B
Revenue (ttm) 849.26M
Net Income (ttm) 20.36M
Shares Out 256.06M
EPS (ttm) 0.08
PE Ratio 162.05
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 24,406,461
Average Volume 15,805,083
Open 11.82
Previous Close 12.81
Day's Range 11.82 - 13.64
52-Week Range 8.58 - 14.23
Beta 0.48
RSI 68.22
Earnings Date Apr 28, 2026

About SHE:300254

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, Ebastine tablets, Tamsulosin hydrochloride sustained release capsule... [Read more]

Sector Healthcare
Founded 2005
Employees 1,196
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300254
Full Company Profile

Financial Performance

In 2024, SHE:300254's revenue was 846.61 million, an increase of 5.92% compared to the previous year's 799.31 million. Earnings were 42.19 million, an increase of 67.45%.

Financial Statements

News

There is no news available yet.